The limitations of currently used biologics that target proinflammatory cytokines, such as TNFα and IL-6R, have led to the search for small molecule inhibitors that are able to target common signaling kinases, which are central to mediating inflammatory signals, with TAK1 emerging as one promising therapeutic target for RA [12,15]. Here, IL6R is linked to rheumatoid arthritis.